These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1950455)

  • 1. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin.
    Cosi V; Lombardi M; Piccolo G; Erbetta A
    Acta Neurol Scand; 1991 Aug; 84(2):81-4. PubMed ID: 1950455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis.
    Selcen D; Dabrowski ER; Michon AM; Nigro MA
    Pediatr Neurol; 2000 Jan; 22(1):40-3. PubMed ID: 10669204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty-six cases and review of current management.
    Mahalati K; Dawson RB; Collins JO; Mayer RF
    J Clin Apher; 1999; 14(1):1-8. PubMed ID: 10355656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term treatment with 7S immunoglobulins in myasthenia gravis. Preliminary clinical results].
    Bamberg C; Janzen RW; Szabados M
    Nervenarzt; 1996 Apr; 67(4):327-32. PubMed ID: 8684513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome after Robotic-Assisted Thymectomy in Children and Adolescents with Acetylcholine Receptor Antibody-Positive Juvenile Myasthenia Gravis.
    Della Marina A; Kölbel H; Müllers M; Kaiser O; Ismail M; Swierzy M; Rueckert JC; Schara U
    Neuropediatrics; 2017 Aug; 48(4):315-322. PubMed ID: 28628938
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose intravenous immunoglobulin in the management of myasthenia gravis.
    Arsura EL; Bick A; Brunner NG; Namba T; Grob D
    Arch Intern Med; 1986 Jul; 146(7):1365-8. PubMed ID: 3718134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-musk antibody after thymectomy in a previously seropositive myasthenic child.
    Saulat B; Maertens P; Hamilton WJ; Bassam BA
    Neurology; 2007 Aug; 69(8):803-4. PubMed ID: 17709714
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
    Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
    J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis.
    Bassan H; Muhlbaur B; Tomer A; Spirer Z
    Pediatr Neurol; 1998 Feb; 18(2):181-3. PubMed ID: 9535308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of patients with Myasthenia gravis from the Henan province, China.
    Gao F; Zhao X; Zhang J; Cui X; Zhang Y; Li Q; Liu P; Fang H; Du Y; Zhang Q; Yang J; Zhang Y
    Muscle Nerve; 2016 May; 53(5):711-6. PubMed ID: 26403759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.
    Pasnoor M; Wolfe GI; Nations S; Trivedi J; Barohn RJ; Herbelin L; McVey A; Dimachkie M; Kissel J; Walsh R; Amato A; Mozaffar T; Hungs M; Chui L; Goldstein J; Novella S; Burns T; Phillips L; Claussen G; Young A; Bertorini T; Oh S
    Muscle Nerve; 2010 Mar; 41(3):370-4. PubMed ID: 19882635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior damage to lower motor neuron triggering myasthenia gravis.
    Steiner I; Goldstein L; Hellmann MA; Lotan I
    Muscle Nerve; 2016 Jun; 54(1):167-9. PubMed ID: 26789735
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C
    Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis: effect of immunoactive therapies.
    Fornádi L; Horváth R; Bárdosi Z; Szobor A
    Acta Med Hung; 1994; 50(1-2):83-92. PubMed ID: 7638045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juvenile myasthenia gravis: treatment with immune globulin and thymectomy.
    Herrmann DN; Carney PR; Wald JJ
    Pediatr Neurol; 1998 Jan; 18(1):63-6. PubMed ID: 9492094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy.
    Oosterhuis HJ; Limburg PC; Hummel-Tappel E; Van den Burg W; The TH
    J Neurol Sci; 1985 Jul; 69(3):335-43. PubMed ID: 4031948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myasthenia gravis in newborn infants--pathological mechanism, clinical symptomatology and therapeutic procedures].
    Krauze M; Musialik E; Swietliński J; Litwa K; Latko E; Górny J; Sobczyk J
    Wiad Lek; 1992 Aug; 45(15-16):610-4. PubMed ID: 1488831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.